美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

VanEck Biotech ETF

232.02

+2.631.15%

盤後：231.90-0.1227-0.05%19:30 EDT

成交量：4,581

成交額：105.91萬

市值：4.66億

市盈率：- -

高：232.10

開：230.06

低：229.59

收：229.39

52周最高：244.35

52周最低：160.91

股本：200.65萬

流通股本：200.65萬

量比：0.48

換手率：0.23%

股息：0.96

股息率：0.42%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Revolution Medicines宣佈Rasonque™（Daraxonrasib）聯合化療獲美國FDA突破性療法認定，用於一線轉移性胰腺癌治療

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

Revolution Medicines獲摩根士丹利首次覆蓋，給予「增持」評級，目標價255美元

118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖

又爆了！集體飆漲！中東，再傳重磅

Stifel上調Revolution Medicines目標價至230美元

安進（AMGN）聯合療法III期臨床達主要終點

安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率

市場風向標：安進股價遭受重創

Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費

Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段

Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利

Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權

安進股價或創二十餘年來最大單日跌幅

福泰製藥(VRTX)股票9月8日盤中下跌3.06%：投資者必看的核心信息

TradingKey中文

吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？

TradingKey中文

諾華公司一款降膽固醇藥物在臨床試驗中失敗，Royalty Pharma股價下跌

安進(AMGN)股票9月8日盤中下跌8.33%：真相來了

TradingKey中文

BUZZ——美國股市動態-Sigma Lithium、Shake Shack、諾華

更正-更新版 1-安進與阿斯利康的藥物組合在晚期研究中幫助肺癌患者延長了生存期

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BBH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":232.024,"timestamp":1789416000000,"preClose":229.3922,"halted":0,"volume":4581,"hourTrading":{"tag":"盘后","latestPrice":231.9013,"preClose":232.024,"latestTime":"19:30 EDT","volume":18,"amount":4175.136,"timestamp":1789428602348,"change":-0.1227,"changeRate":-0.000529,"amplitude":0},"delay":0,"changeRate":0.011472927152710503,"floatShares":2006503,"shares":2006503,"eps":0,"marketStatus":"未開盤","change":2.6318,"latestTime":"09-14 16:00:00 EDT","open":230.06,"high":232.1,"low":229.5938,"amount":1059133.20111,"amplitude":0.010925,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":229.3922,"sharesOutstanding":1976503,"nav":229.3061,"aum":460103384.52,"dividendRate":0.004152,"bidAskSpread":0.001038,"postHourTrading":{"tag":"盘后","latestPrice":231.9013,"preClose":232.024,"latestTime":"19:30 EDT","volume":18,"amount":4175.136,"timestamp":1789428602348,"change":-0.1227,"changeRate":-0.000529,"amplitude":0},"volumeRatio":0.482698,"impliedVol":0.187,"impliedVolPercentile":0.3745},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":2006503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.482698,"shares":2006503,"dividePrice":0.9634,"high":232.1,"amplitude":0.010925,"preClose":229.3922,"low":229.5938,"week52Low":160.91,"pbRate":"--","week52High":244.345,"institutionHeld":0,"latestPrice":232.024,"eps":0,"divideRate":0.004152,"volume":4581,"delay":0,"ttmEps":0,"open":230.06,"prevYearClose":189.2649,"prevWeekClose":229.3922,"prevMonthClose":236.396,"prevQuarterClose":203.2373,"fiveDayClose":241.1222,"twentyDayClose":218.0411,"sixtyDayClose":188.0998},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1165924054","title":"Revolution Medicines宣佈Rasonque™（Daraxonrasib）聯合化療獲美國FDA突破性療法認定，用於一線轉移性胰腺癌治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1165924054","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165924054?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 04:06","pubTimestamp":1789416374,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc.今日宣布，其研发的创新药物Rasonque与化疗药物联用，已获得美国食品药品监督管理局授予的突破性疗法认定。这一认定针对的适应症为一线治疗转移性胰腺癌。此项突破性疗法认定标志着该联合治疗方案在临床试验中展现出显著的治疗潜力，有望为预后极差的转移性胰腺癌患者带来新的治疗选择。这一进展不仅为Revolution Medicines的研发管线注入了强劲动力，也让医学界对攻克胰腺癌这一顽固性疾病增添了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE0009355771.USD","PTH","IE0009354923.USD","CANC","IE00B4R5TH58.HKD","BK4139","IE0002141913.USD","IDNA","IE00B2B36J28.USD","BBH","IE00BJJMRZ35.SGD","RVMD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBPH","LU2322448791.USD","IEHS","HELX","GNOM","LU1992135399.USD","TMED","BIB","FBT","XPH","PPH","BK4588","LU2272731865.HKD","RXL","PBE","LU1992135472.HKD","CANC","SYNB","MEDI","BME","BBP","BBH","XBIX","RSPH","IE00B5TLWC47.USD","IDNA","IBB","BIOY","PJP","IBRN","MRNX","LU2272731600.USD","IEIH","FTXH","AZNH","IYH","LFSC","LU2322448957.HKD","BK4585","PSCH","SBIO","MRNY","WDNA","LU2473716301.USD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186962882","title":"Revolution Medicines獲摩根士丹利首次覆蓋，給予「增持」評級，目標價255美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186962882","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186962882?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:10","pubTimestamp":1789035009,"startTime":"0","endTime":"0","summary":"摩根士丹利近日宣布首次覆盖生物制药公司Revolution Medicines, Inc.，并给予其“增持”评级。该机构将目标股价设定为每股255美元。这一举措标志着华尔街主要投行对这家专注于研发创新疗法的企业前景持乐观态度。值得注意的是，摩根士丹利的这一评级和价格目标，为投资者提供了新的参考坐标。此前，市场对Revolution Medicines的关注度持续攀升，尤其在肿瘤治疗领域，其管线布局备受瞩目。此次覆盖报告的出炉，或将在短期内影响该股的市场情绪与交易动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","BK4139","IE00BJT1NW94.SGD","IE0002141913.USD","LU0109394709.USD","LU0320765992.SGD","RVMD","IE00BFTCPJ56.SGD","IDNA","IE0009355771.USD","PTH","IE00B2B36J28.USD","CANC","IE00BJJMRZ35.SGD","IE0009354923.USD","LU0889565916.HKD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563124","title":"118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["RSPH","159839","PJP","BBP","APXH","BME","MEDI","TMED","PBPH","GSKH","IHE","BBH","IYH","PPH","TRUH","FXH","JDOC","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528665","title":"又爆了！集體飆漲！中東，再傳重磅","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528665","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528665?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:37","pubTimestamp":1789011420,"startTime":"0","endTime":"0","summary":"中午好，在本周二大涨之后，能化板块又爆发了！周四早盘，原油期货主力合约一度涨近10%，纯苯、苯乙烯期货主力合约涨停。截至11:30收盘，原油期货主力合约涨幅有所收窄，纯苯期货主力合约涨 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LU1983299246.USD","BK4585","LU0868494617.USD","LU2112291526.USD","SG9999001440.SGD","BK4139","PJP","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU1571399168.USD","TBXU","LU0289739699.SGD","LU0320765992.SGD","BK4581","IBBQ","LU0889565916.HKD","LU1057294990.SGD","BK4599","IBB","LU0122379950.USD","IE0002141913.USD","IE0009355771.USD","LU1061106388.HKD","LU2089984988.USD","BK4588","PBE","BK4566","BK4534","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4533","BIB","LU2468319806.SGD","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00B2B36J28.USD","AMGN","BBH","LU2242646821.SGD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554138","title":"Stifel上調Revolution Medicines目標價至230美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554138","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666554138?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:17","pubTimestamp":1789010271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0009355771.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00B2B36J28.USD","PTH","IDNA","LU0889565916.HKD","IE00BJT1NW94.SGD","UUP","BBH","IE0009354923.USD","LU0109394709.USD","BK4139","RVMD","CANC","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安進（AMGN）聯合療法III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","AMGN","BK4566","LU0109394709.USD","LU2468319806.SGD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","BK4581","BIB","AZNH","PJP","LU0889565916.HKD","IE0002141913.USD","LU0128525929.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","BBH","IE00B4R5TH58.HKD","LU1571399168.USD","BK4533","LU1023059063.AUD","LU0058720904.USD","LU0868494617.USD","LU2456880835.USD","LU0708994859.HKD","IBBQ","LU2242646821.SGD","LU0289739699.SGD","LU0432979614.USD","LU1829250122.USD","IBB","LU2236285917.USD","IE00B2B36J28.USD","PBE","LU2237443622.USD","LU0029864427.USD","BK4139","BK4568","BK4534","BK4585","LU2237443382.USD","LU1267930573.SGD","LU2462157665.USD","LU2089984988.USD","TBXU","SG9999001440.SGD","AZN","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309213?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","BK4588","BK4534","IE00B4R5TH58.HKD","LU2468319806.SGD","IE00BJT1NW94.SGD","TBXU","LU2242652126.USD","LU0289739699.SGD","LU0320765992.SGD","PBE","BMED","LU2089984988.USD","BK4533","PJP","LU2112291526.USD","IE00B2B36J28.USD","BK4599","MDTX","LU1571399168.USD","AMGN","LU0868494617.USD","LU1057294990.SGD","IE0002141913.USD","PSYK","IE00BFTCPJ56.SGD","LU0122379950.USD","IE0009355771.USD","IBBQ","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4566","IBBJ","LU0889565916.HKD","IBB","LU1023059063.AUD","SG9999001440.SGD","LU1061106388.HKD","BBH","BIB","LU1983299246.USD","BK4585","BK4581","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市場風向標：安進股價遭受重創","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112638879?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"hk","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0320765992.SGD","LU2242652126.USD","IE0002141913.USD","BK4599","LU0109394709.USD","PJP","BK4534","BK4566","PBE","AMGN","LU1571399168.USD","BK4588","LU1061106388.HKD","LU0122379950.USD","LU1983299246.USD","LU1057294990.SGD","SG9999001440.SGD","IBB","LU2468319806.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BIB","BK4533","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU2112291526.USD","LU1023059063.AUD","TBXU","IBBQ","BK4139","LU0289739699.SGD","BK4581","LU2242646821.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","LU1934455194.USD","TMED","LU2087621335.USD","LU1430594728.SGD","LU1778281490.HKD","LU0882574055.USD","LU0965509101.SGD","BK4583","IE00BZ1G4Q59.USD","LU1037948897.HKD","TBXU","IE0002270589.USD","IE00B3T34201.USD","LU0861579265.USD","LU0114720955.EUR","BK4139","IBBQ","LU0823416689.USD","LU0965509010.AUD","LU1066051498.USD","LU2089984988.USD","LU2357627491.SGD","LU0889565916.HKD","LU1674673428.USD","LU0859254822.USD","LU0289739699.SGD","LU0965508806.USD","LU1061106388.HKD","LU1674673691.USD","LU1934455277.USD","LU1839511570.USD","LU1023059063.AUD","BK4585","LU1571399168.USD","BK4578","LU1934455863.HKD","IE00BSNM7G36.USD","LU2324357040.USD","IE00B19Z3B42.SGD","LU0965509283.SGD","IE00B19Z3581.USD","BK4532","IE00BKVL7J92.USD","BK4566","LU1037948541.HKD","SG9999015945.SGD","BBH","LU0320765992.SGD","LU2112291526.USD","BK4568","LU1066053197.SGD","IE00B7SZLL34.SGD","LU0234570918.USD","SG9999015986.USD","LU1057294990.SGD","LU1585245621.USD","LU2468319806.SGD","LU0058720904.USD","LU0122379950.USD","MEDI","BK4588","GILD","BMED","BK4550","IBB","SG9999015952.SGD","SG9999015978.USD","ASMB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0965509101.SGD","LU0234570918.USD","LU0823416689.USD","LU2468319806.SGD","ASMB","BK4532","LU1066053197.SGD","BK4568","LU0289739699.SGD","LU0859254822.USD","SG9999015952.SGD","LU1934455194.USD","LU0889565916.HKD","LU1037948541.HKD","LU0965508806.USD","TMED","LU1057294990.SGD","LU0965509283.SGD","LU1934455863.HKD","LU2089984988.USD","SG9999015945.SGD","LU1674673428.USD","LU0114720955.EUR","BIB","LU1778281490.HKD","BK4588","IE00B7SZLL34.SGD","BK4550","LU2087621335.USD","IE00BZ1G4Q59.USD","LU2112291526.USD","LU1674673691.USD","LU1061106388.HKD","BK4566","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1934455277.USD","LU0058720904.USD","LU1571399168.USD","LU0861579265.USD","LU1585245621.USD","IE00B3T34201.USD","IBB","IE00BSNM7G36.USD","MEDI","LU2324357040.USD","BK4578","SG9999015978.USD","IBBQ","LU0965509010.AUD","BBH","TBXU","IE00BKVL7J92.USD","LU0882574055.USD","LU1430594728.SGD","BK4139","LU1023059063.AUD","LU1839511570.USD","BMED","LU0109394709.USD","LU0122379950.USD","IE0002270589.USD","SG9999015986.USD","BK4583","GILD","BK4585","LU1066051498.USD","LU2357627491.SGD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","SG9999015945.SGD","LU0289739699.SGD","LU1061106388.HKD","TBXU","MEDI","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU1934455277.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU0965509283.SGD","LU0859254822.USD","LU1571399168.USD","LU1674673428.USD","LU2089984988.USD","LU0122379950.USD","LU2468319806.SGD","LU0965509010.AUD","BK4578","LU1057294990.SGD","LU1430594728.SGD","LU1066053197.SGD","GILD","LU1585245621.USD","BIB","BK4550","BK4532","BMED","LU1778281490.HKD","LU0234570918.USD","LU1066051498.USD","LU1023059063.AUD","LU0965508806.USD","BK4568","BK4588","LU1674673691.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0882574055.USD","LU1037948541.HKD","IBBQ","LU0965509101.SGD","LU0058720904.USD","BBH","SG9999015986.USD","ASMB","IBB","IE00B19Z3B42.SGD","IE0002270589.USD","LU0109394709.USD","LU0823416689.USD","BK4139","LU2357627491.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","SG9999015978.USD","TMED","LU1037948897.HKD","LU1934455863.HKD","SG9999015952.SGD","BK4583","LU2324357040.USD","BK4566","LU1839511570.USD","LU0861579265.USD","LU1934455194.USD","BK4585","LU2112291526.USD","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU2357627491.SGD","SG9999015978.USD","LU1066051498.USD","LU1934455194.USD","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU1674673428.USD","TMED","SG9999015952.SGD","IBB","ASMB","LU1023059063.AUD","LU0320765992.SGD","BK4583","BK4588","LU2087621335.USD","BK4585","IBBQ","LU0965509010.AUD","LU1778281490.HKD","LU0965508806.USD","LU1585245621.USD","BK4578","BK4550","IE00B19Z3581.USD","LU0823416689.USD","LU0882574055.USD","LU2089984988.USD","TBXU","LU0289739699.SGD","LU0861579265.USD","LU0965509283.SGD","IE00B7SZLL34.SGD","LU1037948541.HKD","LU1571399168.USD","LU1674673691.USD","SG9999015986.USD","IE0002270589.USD","LU0109394709.USD","LU1430594728.SGD","BK4568","LU0889565916.HKD","LU1934455277.USD","BBH","BMED","LU2112291526.USD","BIB","LU0058720904.USD","LU0859254822.USD","LU1057294990.SGD","IE00B3T34201.USD","MEDI","LU2324357040.USD","LU0114720955.EUR","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0234570918.USD","LU0965509101.SGD","LU1037948897.HKD","IE00BSNM7G36.USD","LU1839511570.USD","LU2468319806.SGD","LU1066053197.SGD","LU1934455863.HKD","BK4532","GILD","SG9999015945.SGD","BK4139","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111756325","title":"安進股價或創二十餘年來最大單日跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111756325","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111756325?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 02:23","pubTimestamp":1788891793,"startTime":"0","endTime":"0","summary":"安进公司股价近期重挫逾9%，这一跌幅令这家生物技术巨头有望迎来自2000年10月以来最惨淡的单日表现。此番暴跌的导火索，源于诺华制药宣布其心脏病药物pelacarsen在降低心血管事件风险方面未能优于安慰剂，试验宣告失败。周二，礼来股价小幅下挫1.9%。安进的跌势因BMO资本市场的下调评级而进一步加剧，使其沦为标普500指数和纳斯达克100指数中的最大输家。","market":"hk","thumbnail":"https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0320765992.SGD","LU2242652126.USD","IE0002141913.USD","BK4599","LU0109394709.USD","PJP","BK4534","BK4566","PBE","AMGN","LU1571399168.USD","BK4588","LU1061106388.HKD","LU0122379950.USD","LU1983299246.USD","LU1057294990.SGD","SG9999001440.SGD","04332","IBB","LU2468319806.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BIB","BK4533","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU2112291526.USD","LU1023059063.AUD","TBXU","IBBQ","BK4139","LU0289739699.SGD","BK4581","LU2242646821.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374214","title":"福泰製藥(VRTX)股票9月8日盤中下跌3.06%：投資者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374214","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374214?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 02:16","pubTimestamp":1788891392,"startTime":"0","endTime":"0","summary":"• Vertex 股价在反弹至接近52周高点后遭遇波动与获利回吐。\n• 对 Crinetics 的收购整合要到2029年才能实现非GAAP增盈。\n• 技术指标显示 MACD 呈中性，RSI 呈中性，威廉指标（Williams %R）呈超卖状态。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156640-market-movers-vrtx-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","BK4532","LU1093756168.USD","SG9999013999.USD","BK4585","BK4139","IE00B19Z3581.USD","IE00B4R5TH58.HKD","LU0061475181.USD","IE00B894F039.SGD","IE0002141913.USD","BK4533","LU1069344957.HKD","LU0289739699.SGD","LU0234570918.USD","LU1093756325.SGD","LU2362541513.USD","IBBQ","LU0079474960.USD","GNMX","IE00BJT1NW94.SGD","LU1585245621.USD","IE0002270589.USD","SG9999001176.USD","IE0009355771.USD","LU1674673428.USD","SG9999001176.SGD","BIB","LU1778281490.HKD","LU1674673691.USD","LU2362541273.HKD","IE00B19Z9Z06.USD","LU1035775433.USD","LU2417539215.USD","PBE","SGXZ57979304.SGD","LU2089984988.USD","LU1430594728.SGD","BK4588","IDNA","LU0432979614.USD","TBXU","VRTX","LU2362540622.SGD","LU0417517546.SGD","IE00B2B36J28.USD","LU0889565916.HKD","BBH","LU2237438978.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374570","title":"吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374570","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374570?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 01:16","pubTimestamp":1788887780,"startTime":"0","endTime":"0","summary":"• 吉利德在经历了长达数月的持续上涨后，因获利回吐而出现回调。\n• 强劲的第二季度营收主要受其旗舰 HIV 和 Trodelvy 产品线的推动。\n• 分析师维持“买入”评级，平均目标价为 157.79 美元。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156554-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU0965509101.SGD","LU2324357040.USD","LU0114720955.EUR","IBB","LU0289739699.SGD","TBXU","IBBQ","BBH","IE00BSNM7G36.USD","LU1839511570.USD","BK4578","LU1674673691.USD","LU1674673428.USD","LU0823416689.USD","LU1571399168.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","MEDI","IE00BZ1G4Q59.USD","SG9999015945.SGD","BMED","GILD","IE0002270589.USD","LU1778281490.HKD","LU1934455277.USD","LU2112291526.USD","IE00B3T34201.USD","TMED","BK4583","IE00B19Z3581.USD","LU0109394709.USD","LU2087621335.USD","LU1430594728.SGD","BIB","LU0122379950.USD","BK4568","LU0861579265.USD","LU1023059063.AUD","LU1037948541.HKD","BK4585","SG9999015978.USD","SG9999015986.USD","LU0965508806.USD","BK4532","IE00B19Z3B42.SGD","LU0859254822.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371445","title":"諾華公司一款降膽固醇藥物在臨床試驗中失敗，Royalty Pharma股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371445","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371445?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 00:41","pubTimestamp":1788885660,"startTime":"0","endTime":"0","summary":"——Royalty Pharma** RPRX重申“其2030年投资组合收入目标为47亿美元或更高”** 计入本交易日涨幅，该股今年以来累计上涨54.7%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T4501DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU0289739699.SGD","LU1061106388.HKD","TBXU","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0889565916.HKD","LU1571399168.USD","LU2089984988.USD","LU0122379950.USD","LU2468319806.SGD","LU1057294990.SGD","LU1983299246.USD","IE00BFTCPJ56.SGD","BK4581","BK4007","BIB","LU0868494617.USD","LU1023059063.AUD","SG9999001440.SGD","BK4599","BK4588","IHE","IBBQ","IE00BJJMRZ35.SGD","BBH","LU0058720904.USD","IBB","LU0109394709.USD","IE0002141913.USD","RPRX","LU2242652126.USD","BK4139","PJP","LU0320765992.SGD","BK4533","IE00B4R5TH58.HKD","PBE","IE0009355771.USD","IONS","BK4566","BK4534","AMGN","BK4585","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376637","title":"安進(AMGN)股票9月8日盤中下跌8.33%：真相來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376637","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376637?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 22:16","pubTimestamp":1788876978,"startTime":"0","endTime":"0","summary":"• 诺华 pelacarsen 试验失败，加大了安进竞品 olpasiran 的临床不确定性。\n• 出于对估值的担忧，BMO Capital 将安进的评级从“跑赢大盘”下调至“与大盘持平”。\n• 技术指标显示，安进的 RSI 为 40.256，威廉指标（Williams %R）为 97.857。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156239-market-movers-amgn-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","BIB","LU2468319806.SGD","AMGN","BK4588","IBBQ","LU0320765992.SGD","LU2112291526.USD","LU1061106388.HKD","LU2242652126.USD","BK4585","IE0002141913.USD","BK4139","LU2242646821.SGD","PJP","BK4566","IE0009355771.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU0109394709.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU2089984988.USD","BK4599","LU0122379950.USD","IBB","LU0868494617.USD","LU0889565916.HKD","LU1023059063.AUD","LU1057294990.SGD","LU1571399168.USD","BK4533","LU1983299246.USD","BK4534","IE00B4R5TH58.HKD","TBXU","BK4581","PBE","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375206","title":"BUZZ——美國股市動態-Sigma Lithium、Shake Shack、諾華","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375206","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375206?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:58","pubTimestamp":1788875887,"startTime":"0","endTime":"0","summary":"BUZZ——美国股市动态-Sigma Lithium、Shake Shack、诺华工作区中用于查询单只股票行情的搜索字符串：STXBZ《今日展望》通讯：https://refini.tv/3LI4BU7《晨间新闻简报》：https://refini.tv/3dKUyB8路透9月8日-周二开盘时，华尔街主要股指涨跌不一，中东地区新一轮冲突推动油价升至7月下旬以来的最高水平，而市场正在等待本周晚些时候","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S45014M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU1548497426.USD","BK4566","IE00B66KJ199.SGD","LU0345769631.USD","BK4131","BE","LU1861559042.SGD","UPGR","BSX","IE00BBT3K403.USD","IONC","IONS","LU0868494617.USD","LU2264538146.SGD","PBE","LU2357125470.USD","BK4504","LU2357305700.SGD","LU0306806265.USD","LU0058720904.USD","LU0128526141.USD","FRNW","LU0138981039.USD","IE00BJT1NW94.SGD","LU1066053197.SGD","LU1093756168.USD","LU1366192091.USD","LU0320765992.SGD","LU2491050071.SGD","LU0070302665.USD","LU0187121727.USD","ICLN","IE000M9KFDE8.USD","BK4556","BK4179","BEG","LU0433182093.SGD","IE00B3T34201.USD","LU1023059063.AUD","SHAK","LU0456855351.SGD","BK4567","SMOG","LU0122379950.USD","BK4209","LU1989764748.USD","LU2491049909.HKD","XES","IE00BLSP4239.USD","EGGY","CTEC","LU1571399168.USD","LU1066051498.USD","LU2543165471.USD","BEC","BK4120","LU0321505439.SGD","LU0823414478.USD","LU1878469433.USD","BK4533","LU0320765489.SGD","PHVS","LU1291159041.SGD","LU1989764664.SGD","LU0476273544.USD","RGTX","LU2242649171.HKD","LU0306807586.USD","BK4121","LU0345769128.USD","LU0823414551.USD","LU0985489474.SGD","LU0225771236.USD","BK4141","LU1720051108.HKD","LU1057294990.SGD","OZEM","BK4588","IE00B7SZL793.SGD","IE0031619046.USD","LU2265009873.SGD","LU2242646821.SGD","WQTM","TBXU","BK4585","LU1989772840.SGD","04332","LU2294711713.HKD","BK4168","IE00B19Z3B42.SGD","LU0234572021.USD","IONQ","LU0957808578.USD","OIH","PJP","LU1894683348.USD","BK4599","CQTM","ROIV","LU1720051017.SGD","SRPT","LU2468319806.SGD","SG9999001176.SGD","LU1983299246.USD","BK4534","LU0077335932.USD","LU0211331839.USD","USNG","BK4102","ALV","IE0009354923.USD","PPH","LU0353189763.USD","CHRW","LU0823416689.USD","RGTU","LU0114720955.EUR","LU0444971666.USD","LU2362540622.SGD","QTUP","LU0011850046.USD","DYN","LU0029874061.USD","LU1791710582.SGD","LU0878866978.SGD","SGML","VTWG","RGTC","IBAT","LU0225283273.USD","LU2087625088.SGD","BK4602","IE00B19Z4B17.USD","BK4578","IOYY","WATS","SEI","LU1153585028.USD","LU2362541513.USD","LU2506952170.USD","BK4581","LU1061106388.HKD","LU2249611893.SGD","LU0170899867.USD","LU0048584097.USD","LU0353189680.USD","BIB","LU0266013472.USD","VCLN","UNFI","LU0882574055.USD","SGXZ57979304.SGD","LU0889565916.HKD","SG9999001440.SGD","LU0289739699.SGD","NTLA","IONL","HYDR","IE00BJJMRZ35.SGD","LU2098885051.SGD","BK4592","IBBQ","LU2491050154.USD","BK4541","SG9999002232.USD","BK4124","IE0009355771.USD","LU2506951958.HKD","BK4597","LU1989772923.USD","LU0238689110.USD","BK4082","LU0985481810.HKD","LU1883839398.USD","LU2506951792.HKD","LU2596442595.SGD","LU0068578508.USD","LU0225284248.USD","MEDX","IE00B4R5TH58.HKD","LU1064131342.USD","LU1791710400.SGD","BEZ","IE00BFTCPJ56.SGD","BK4591","BK4532","LU1804176565.USD","LU2362541273.HKD","RGTZ","LU0950375773.USD","LU1642822529.SGD","LU0432979614.USD","LU2324357040.USD","IE0002270589.USD","SG9999002224.SGD","LU2242652126.USD","BEX","IONX","LU0109394709.USD","LU0528227936.USD","LU2244417387.USD","BBH","IE00BLSP4452.SGD","SG9999003800.SGD","BK4139","LU1894683264.USD","GNOM","BK4568","ILMN","RGTI","BK4170","IE0002141913.USD","RGYY","LU1718418525.SGD","LU1989771016.USD","IBB","SG9999001176.USD","CNRG","LU2089984988.USD","LU0208291251.USD","LU2506951875.HKD","LU1489326972.SGD","ABM","BK4548","SG9999011175.SGD","LU0251132253.USD","LU1815336760.USD","BK4182","GNMX","LU2112291526.USD","LU0823417653.USD","LU1988902786.USD","BK4505","SIMS","LU0823417737.USD","BK4007","BK4535","NVS","LU0321505868.SGD","IE00B2B36J28.USD","IONZ","LU0444973449.USD","LU1093756325.SGD","LU1861558580.USD","SG9999013999.USD","PTH","SRPU","BK4550","IE00B19Z3581.USD","LU0267386448.USD","LU1303367103.USD","ZAP","PFE","IE0034235188.USD","BHVN","LU2506952097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665251375","title":"更正-更新版 1-安進與阿斯利康的藥物組合在晚期研究中幫助肺癌患者延長了生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665251375","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665251375?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:52","pubTimestamp":1788875520,"startTime":"0","endTime":"0","summary":"更新版 1-阿斯利康的联合用药方案在晚期研究中帮助肺癌患者延长了生存期全文补充了有关临床试验和背景的详细信息路透9月8日-阿斯利康AZN.L周二表示，其抗癌药物Imfinzi与安进的AMGN.O靶向免疫疗法Imdelltra联合使用，在一项晚期临床试验中显著提高了广泛期小细胞肺癌患者的总生存期。癌症治疗药物占阿斯利康销售额近一半；2025年，在该公司256.2亿美元的肿瘤产品收入中，Imfinzi贡献了60.6亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T45013T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930490.SGD","PBE","LU0029864427.USD","LU0211326755.USD","LU1196032939.SGD","TBXU","LU0738911758.USD","BBH","LU0889566641.SGD","LU1153585028.USD","LU0158827948.USD","LU0211328371.USD","LU2237443382.USD","LU0969580561.USD","BK4588","AMGN","LU2108987350.USD","LU2468319806.SGD","LU1046234339.USD","IBB","LU2242646821.SGD","LU0997586432.USD","PJP","LU0553294199.USD","LU2089284900.SGD","LU1273509221.SGD","LU0784384876.USD","LU0823416689.USD","LU0171293334.USD","LU2279689827.SGD","BK4533","LU2237443622.USD","BK4585","03165","LU0058720904.USD","IBBQ","AZN.UK","LU0557290698.USD","LU0211327993.USD","LU0792757196.USD","LU0887340254.USD","BIB","LU1267930813.SGD","LU2125909593.SGD","LU0708994859.HKD","IE0009355771.USD","LU1989771016.USD","LU1267930227.SGD","LU0289739699.SGD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":187,"code":"91000000","status":"200"}]}}